Literature DB >> 36131046

The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis.

Belinda Lennox1, Wenzheng Xiong2,3, Patrick Waters4, Alasdair Coles5, Peter B Jones6, Tianrong Yeo2,7,8, Jeanne Tan May May7,8, Ksenija Yeeles9, Daniel Anthony2, Fay Probert3.   

Abstract

A range of studies suggest that a proportion of psychosis may have an autoimmune basis, but this has not translated through into clinical practice-there is no biochemical test able to accurately identify psychosis resulting from an underlying inflammatory cause. Such a test would be an important step towards identifying who might require different treatments and have the potential to improve outcomes for patients. To identify novel subgroups within patients with acute psychosis we measured the serum nuclear magnetic resonance (NMR) metabolite profiles of 75 patients who had identified antibodies (anti-glycine receptor [GlyR], voltage-gated potassium channel [VGKC], Contactin-associated protein-like 2 [CASPR2], leucine-rich glioma inactivated 1 [LGI1], N-methyl-D-aspartate receptor [NMDAR] antibody) and 70 antibody negative patients matched for age, gender, and ethnicity. Clinical symptoms were assessed using the positive and negative syndrome scale (PANSS). Unsupervised principal component analysis identified two distinct biochemical signatures within the cohort. Orthogonal partial least squared discriminatory analysis revealed that the serum metabolomes of NMDAR, LGI1, and CASPR2 antibody psychosis patients were indistinct from the antibody negative control group while VGKC and GlyR antibody patients had significantly decreased lipoprotein fatty acids and increased amino acid concentrations. Furthermore, these patients had more severe presentation with higher PANSS scores than either the antibody negative controls or the NMDAR, LGI1, and CASPR2 antibody groups. These results suggest that a proportion of patients with acute psychosis have a distinct clinical and biochemical phenotype that may indicate an inflammatory subtype.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36131046     DOI: 10.1038/s41380-022-01784-4

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   13.437


  43 in total

1.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

2.  Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study.

Authors:  Belinda R Lennox; Emma C Palmer-Cooper; Thomas Pollak; Jane Hainsworth; Jacqui Marks; Leslie Jacobson; Bethan Lang; Hannah Fox; Berne Ferry; Linda Scoriels; Hannah Crowley; Peter B Jones; Paul J Harrison; Angela Vincent
Journal:  Lancet Psychiatry       Date:  2016-12-08       Impact factor: 27.083

3.  Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study.

Authors:  Michael E Benros; Philip R Nielsen; Merete Nordentoft; William W Eaton; Susanne O Dalton; Preben B Mortensen
Journal:  Am J Psychiatry       Date:  2011-12       Impact factor: 18.112

Review 4.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.

Authors:  Josep Dalmau; Eric Lancaster; Eugenia Martinez-Hernandez; Myrna R Rosenfeld; Rita Balice-Gordon
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

5.  Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.

Authors:  Jennie G Pouget; Buhm Han; Yang Wu; Emmanuel Mignot; Hanna M Ollila; Jonathan Barker; Sarah Spain; Nick Dand; Richard Trembath; Javier Martin; Maureen D Mayes; Lara Bossini-Castillo; Elena López-Isac; Ying Jin; Stephanie A Santorico; Richard A Spritz; Hakon Hakonarson; Constantin Polychronakos; Soumya Raychaudhuri; Jo Knight
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

6.  N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.

Authors:  Sarosh R Irani; Katarzyna Bera; Patrick Waters; Luigi Zuliani; Susan Maxwell; Michael S Zandi; Manuel A Friese; Ian Galea; Dimitri M Kullmann; David Beeson; Bethan Lang; Christian G Bien; Angela Vincent
Journal:  Brain       Date:  2010-06       Impact factor: 13.501

7.  Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses.

Authors:  Adam Al-Diwani; Thomas A Pollak; Alexander E Langford; Belinda R Lennox
Journal:  Front Psychiatry       Date:  2017-02-06       Impact factor: 4.157

8.  Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.

Authors:  Maciej Jurynczyk; Fay Probert; Tianrong Yeo; George Tackley; Tim D W Claridge; Ana Cavey; Mark R Woodhall; Siddharth Arora; Torsten Winkler; Eric Schiffer; Angela Vincent; Gabriele DeLuca; Nicola R Sibson; M Isabel Leite; Patrick Waters; Daniel C Anthony; Jacqueline Palace
Journal:  Acta Neuropathol Commun       Date:  2017-12-06       Impact factor: 7.801

9.  Depressive symptoms in non-alcoholic fatty liver disease are identified by perturbed lipid and lipoprotein metabolism.

Authors:  Daniel E Radford-Smith; Preya J Patel; Katharine M Irvine; Anthony Russell; Dan Siskind; Daniel C Anthony; Elizabeth E Powell; Fay Probert
Journal:  PLoS One       Date:  2022-01-06       Impact factor: 3.240

10.  Plasma Nuclear Magnetic Resonance Metabolomics Discriminates Between High and Low Endoscopic Activity and Predicts Progression in a Prospective Cohort of Patients With Ulcerative Colitis.

Authors:  Fay Probert; Alissa Walsh; Marta Jagielowicz; Tianrong Yeo; Timothy D W Claridge; Alison Simmons; Simon Travis; Daniel C Anthony
Journal:  J Crohns Colitis       Date:  2018-11-15       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.